Educational information only — not medical advice. Most peptides here are not FDA-approved.
MyPeps
Calculator

FDA's 2026 peptide compounding changes, explained

October 1, 2026 · 4 min read

In April the FDA took 12 peptides off its compounding safety-concern list, and in July an advisory panel voted on seven. Here is what each step means, and what it doesn't.

In 2026, US rules for compounding popular peptides started moving after years of standing still. There were two big steps: an FDA list change in April, and an advisory committee vote in July. Headlines have often made these sound bigger than they are. This post explains what actually changed.

First, a quick primer on compounding

Compounding is when a licensed pharmacy makes a medicine for a specific patient from a prescription. Under section 503A of US drug law, a pharmacy can only compound with a raw ingredient (a "bulk drug substance") if that ingredient meets certain conditions. One way to qualify is to be on the FDA's 503A bulks list.

While that list is being built, the FDA sorts nominated ingredients into interim groups:

  • Category 1: under review, and the FDA generally doesn't take action against pharmacies that use them in the meantime.
  • Category 2: the FDA has flagged "significant safety risks". Pharmacies that compound with them face enforcement.
  • Category 3: nominated without enough supporting information.

Since 2023, many popular peptides had sat in Category 2. That effectively stopped legitimate pharmacies from making them, while the same peptides stayed widely available online as "research chemicals".

April 2026: 12 peptides leave Category 2

On April 15, 2026, the FDA announced it would remove 12 peptides from Category 2, effective about a week later. The reason was procedural: the people or companies who had nominated them withdrew their nominations. The 12 were:

The FDA was clear that removal "does not render these bulk drug substances eligible for compounding." The peptides were not moved to Category 1 or added to the bulks list. They are now in a pending-review state. The FDA also said it would bring them to its Pharmacy Compounding Advisory Committee (PCAC): first at a meeting on July 23–24, 2026, and the rest at a second meeting before the end of February 2027.

July 2026: the advisory committee votes

On July 23–24, the PCAC looked at seven peptides, each for specific proposed uses. The FDA's own scientists had recommended against adding any of the seven. The committee disagreed on six of them:

  • BPC-157 (ulcerative colitis): 8 for, 6 against, 1 abstention. Recommended.
  • KPV (wound healing, inflammatory conditions): 8–6, 1 abstention. Recommended.
  • TB-500 (wound healing): 8–6, 1 abstention. Recommended.
  • MOTS-c (obesity, osteoporosis): 7–5, 2 abstentions. Recommended.
  • Semax (cerebral ischemia, migraine, trigeminal neuralgia): 8–5. Recommended.
  • Epitalon (insomnia): 7 for, 1 abstention. Recommended. Published reports differ on whether 4 or 5 members voted against.
  • Emideltide / DSIP (insomnia, opioid withdrawal): 6 for, 7 against, 1 abstention. Not recommended.

All of these votes were close. In written reviews, FDA staff pointed to limited human data, uncertainty about exactly what these peptides are chemically, and a risk of immune reactions from impurities or clumped peptide. At the meeting, one FDA official, Russell Wesdyk, put the identity problem this way: "We've never faced a problem of, 'What is it?'" Panelists who voted no worried that listing the peptides would make them look as rigorously tested as approved drugs.

The second meeting, due by February 2027, is expected to cover GHK-Cu, Dihexa, LL-37, PEG-MGF and Melanotan II.

What a "yes" vote means, and what it doesn't

The PCAC is an advisory body. Its votes do not bind the FDA, and they change nothing legally on their own. Here is what has to happen next:

  1. The FDA decides whether to accept each recommendation. It can disagree, and its staff already have.
  2. If it accepts, it publishes a proposed rule, opens a public comment period, then publishes a final rule.
  3. Only after the final rule takes effect can a 503A pharmacy legally compound that peptide. Even then, it needs a prescription for a specific patient.

There is no legal deadline for any of these steps. Lawyers who follow this area say the process has often taken years. As of early October 2026, we have not found a proposed rule for any of the six peptides. As one pharmacist wrote in Pharmacy Times after the vote: "Nothing is legal today that wasn't legal 2 weeks ago."

Even being added to the bulks list is not FDA approval. An approved drug has passed controlled trials showing it is safe and effective, and its manufacturing is inspected. A compounded peptide made from a listed ingredient has passed neither test. Being on the list just means a pharmacy is allowed to make it for a patient.

What this means for readers

  • None of these peptides is an FDA-approved drug, and none has become approved through this process.
  • "Research use only" vials sold online were not affected by these decisions. They are still unregulated products with no checks on quality or sterility.
  • Several of these peptides are also banned in sport. BPC-157 is on WADA's prohibited list, for example.

Each peptide page on MyPeps has a regulatory section that we update as the rules change. Start with BPC-157, TB-500 or KPV. Always check the FDA's 503A categories page for the current status.

This is educational information, not medical advice.

Sources

Get the next one by email

New posts, price drops and FDA or WADA changes. Pick what you want.

What to email you about

One email to confirm, then only what you picked. Unsubscribe from any email.